N/A N=194 Short Stay Unit vs Hospitalization in Acute Heart Failure
Acute Heart Failure
Primary: Days Alive and Out of Hospital — 26.9; 25.4 Days Alive and Out of Hospital
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=4,313 Length of Stay in NVAF Patients Hospitalized and Initiated With Dabigatran or Warfarin in Japan
Atrial Fibrillation
Primary: Length of Stay (LoS) From Treatment of Oral Anticoagulant Initiation to Hospital Discharge Without Consideration of Baseline — 9.8; 14.9 Months — p=<0.001
N/A N=129 Reducing Length of Stay for Veterans Hospitalized With Pneumonia
Pneumonia
Primary: Length of Hospital Stay — 7.3; 5.8 Days
N/A N=5,834 European Mortality & Length Of Intensive Care Unit (ICU) Stay Evaluation (ELOISE)
Critical Illness
Primary: Vital Status at Hospital Discharge — 1232; 165 participants
N/A N=1,500 Hospital to Home Outcomes
Focus: Hospitalized Patients
Primary: Number of Participants With Any Occurrence of Unplanned Re-hospitalization and/or Any Emergency/Urgent Care Visits Within 30 Days of Hospital Discharge — 133; 105…
N/A N=178 Evaluation of Providing Coffee to Patients Postoperatively to Decrease Length of Stay in the PACU
PACU Length of Stay · Postoperative Nausea · Postoperative Vomiting
Primary: PACU Length of Stay — 82; 76 minutes — p=0.12
N/A N=6 Utility of Continuous Pulse Oximetry for Pediatric Patients With Stable Respiratory Illness
Respiratory Disease · Asthma in Children · Pneumonia in Children
Primary: Length of Stay, Measured in Days — 1.15; 1.04 days
Phase 4 N=63 Intraoperative Infusion of Precedex to Reduce Length of Stay After Lumbar Spine Fusion
Spinal Fusion Acquired · Spinal Stenosis · Lesions of Lumbosacral Intervertebral Disc
Primary: Time Required After Surgery to Reach Fitness for Discharge From Hospital — 3.2; 3.2 days — p=0.36
Phase 1 N=6 Disposition of 14C-LY3009104 Following Oral Administration in Healthy Human Subjects
Healthy Volunteers
Primary: Percentage of the Total Radioactive Dose Administered Excreted From Urine and Feces — 75.2; 19.9 percentage of total radioactivity
N/A N=69 Long-Term Outcomes for Lumbar Spinal Stenosis Patients Treated With X STOP®
Lumbar Spinal Stenosis
Primary: Treatment Success Rates (At ≥ 5 Years) — 40.8; 30.8; 38.7; 53.8 percentage of participants
N/A N=122 The Effect of Etomidate on Patient Outcomes After Single Bolus Doses
Sepsis · Trauma
Primary: Length of Stay — 9.5; 7.3 days
N/A N=104 Spontaneous Void Requirements for Patients Undergoing Ambulatory Anorectal Surgery
Complications, Postoperative
Primary: PACU Time — 129.1; 210.0 Minutes
Phase 4 N=27 Preemptive Ethanol Lock Therapy in Pediatric Bloodstream Infection
Leukemia · Lymphoma · Blood Disorders
Primary: Length of Stay (LOS) in Those With 14 Confirmed Catheter Related Infection Cases — 124; 208 HOURS
N/A N=24 Longevity of Multi-Slitted Catheter With Lantern Technology
Insulin Dependent Diabetes Mellitus 1
Primary: Time to Infusion Set Failure — 8.0 days
N/A N=335 Evaluating the Impact of the Bridge Clinic in Patients With Opioid Use Disorder
Opioid Use · Opioid-use Disorder
Primary: Hospital Length of Stay — 232.1; 215.0 Hours
N/A N=97 Stand if You Can: A Standing Intervention in Long Term Care
Frailty · Sedentary Behavior · Physical Disability
Primary: Changes in Walking Speed — 0.34; 0.43; 0.35; 0.40 m/s
N/A N=1,584 Volatile Anesthetic Choice and Duration of Hospitalization: A Quality Improvement and Cost-control Project
Duration of Hospitalization
Primary: Hospital Length of Stay — 4.9; 4.4 Days — p=0.24
Phase 2 N=246 Alternative Schedule Study For VLA15, a Vaccine Candidate Against Lyme Borreliosis
Lyme Borreliosis
Primary: GMTs for IgG Against Each OspA Serotype — 278.5; 274.7; 21.0; 545.2 Units per milliliter (U/mL)
N/A N=178 Length of Cook Catheter Placement and Induction of Labor
Induction of Labor
Primary: Time to Delivery — 19.2; 24.3 hours — p=0.04
N/A N=668 Prevalence of Chronic Inebriates to the Emergency Department and Suitability for Sobering House Services
Alcohol Intoxication
Primary: Intoxicated Patients Eligible for a Sobering House — 163 Participants
N/A N=366 Incubator Weaning of Moderately Preterm Infants
Infant, Newborn · Infant, Moderate Preterm
Primary: Length of Hospital Stay (LOS) From Birth to Discharge (up to 120 Days) — 43; 41 days
N/A N=21 Duration of Antibiotic Treatment for Early VAP (DATE) Trial
Early Ventilator Associated Pneumonia
Primary: Clinical Response — 2.9; 2.9 score on a scale — p=<0.01
N/A N=83 Remote Device Interrogation In The Emergency Department
Heart Disease · Cardiovascular Disease · Heart Failure
Primary: Time to Interrogation — 25; 210 Minutes
N/A N=205 Longitudinal Evaluation of Silicone Hydrogel (LASH) Study
Corneal Infiltrates
Primary: Cumulative Incidence of Corneal Inflammatory Events — 26.7 annual incidence per 100 subjects
Phase 1 N=6 A Study of LY3337641 in Healthy Male Participants
Healthy
Primary: Urinary Excretion of Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered — 2.9 Percentage of total dose
N/A N=794 LEARN-6™: A Prospective, Observational Nursing Home Study
Anemia · Chronic Kidney Disease
Primary: Total Distance Walked or Wheeled in a Maximum of 10 Minutes at Each Visit — 210.0; 253.1; 210.0; 246.5 feet
N/A N=610 Home Away From Home - Medical Outcomes
Acute Myeloid Leukemia · Neutropenia · Bacteremia
Primary: Occurrence of Post-chemotherapy Bacteremia — 22; 81 Participants
N/A N=91 Vibratory PEP Device and Hospital Length of Stay for Acute Exacerbation of COPD
Chronic Obstructive Pulmonary Disease
Primary: Length of Stay — 4.8; 3.2 days
N/A N=2,655 Edoxaban Treatment in Routine Clinical Practice in Patients With Venous Thromboembolism in Europe
Venous Thromboembolism
Primary: Percentage of Participants With At Least 1 Symptomatic Venous Thromboembolism Recurrence - Overall — 3.8 Percentage of VTE recurrence
N/A N=140 An Observational Study of the Real Life Management of the Psoriasis Patients Treated With Enbrel According to the New Reimbursement Criteria
Plaque Psoriasis Patients
Primary: Number of Weeks of Etanercept Treatment — 48.1874 weeks